Rate My Professor Remi Adelaiye-Ogala

Remi M. Adelaiye-Ogala, PhD, serves as Assistant Professor in the Department of Medicine, Division of Hematology/Oncology, and Clinical Assistant Professor in the Department of Urology within the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, where she joined as a tenure-track faculty member in 2022. She holds additional roles as Graduate Faculty Member in Medicine and Adjunct Research Assistant Professor in Pharmacology and Toxicology since 2021. Prior appointments include Research Assistant Professor in the Department of Medicine from 2021 to 2022. Adelaiye-Ogala earned her PhD in Cancer Pathology from the University at Buffalo in collaboration with Roswell Park Cancer Institute Division in 2017 and her BS from the State University of New York at Fredonia in 2009. She completed a postdoctoral fellowship at the Center for Cancer Research, National Cancer Institute, NIH, in 2020.

Her research program investigates mechanistic determinants of therapeutic resistance in genitourinary cancers, with emphasis on molecular regulation of signaling pathways in prostate and renal cancers through epigenetics, genomics and proteomics, transcriptomics, preclinical models, and translational strategies to overcome drug resistance. Ongoing projects include targeting drivers of androgen receptor cistrome reprogramming in advanced aggressive prostate cancer, posttranslational modulations and dynamics of pro-oncogenic glucocorticoid receptor activity in enzalutamide-resistant prostate cancers, and development of patient-derived xenograft and organoid models from underrepresented populations. She received a five-year, $3 million NIH R01 grant from the National Cancer Institute as a MERIT R37 award titled “Posttranslational Modifications of Glucocorticoid Receptor Associated With Drug-Resistance in Prostate Cancer” and the Prostate Cancer Foundation Young Investigator award. Key publications include “MECOM Function is Critical for AR-Driven Treatment-Resistant Prostate Cancer” (Cancer Research, 2026), “Coactivator Networks Orchestrating Noncanonical AR Programs in Enzalutamide-Resistant CRPC” (Frontiers in Oncology, 2026), “Small-molecule disruption of androgen receptor-dependent chromatin clusters” (Proceedings of the National Academy of Sciences, 2024), “Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer” (Molecular Cancer Therapeutics, 2023), and “Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor” (Molecular Cancer Therapeutics, 2020).